EcoR1 Capital’s Atea Pharmaceuticals AVIR Stock Holding History

EcoR1 Capital’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,341,653	Closed	-$11.2M	–	48
2024 Q4	$11.2M	Sell	3,341,653 -2,100,243	-39%	-$6.98M	0.42%	37
2024 Q3	$18.2M	Hold	5,441,896	–	–	0.62%	35
2024 Q2	$18M	Sell	5,441,896 -703,965	-11%	-$2.62M	0.55%	37
2024 Q1	$24.8M	Sell	6,145,861 -850,000	-12%	-$3.33M	0.63%	30
2023 Q4	$21.3M	Hold	6,995,861	–	–	0.55%	30
2023 Q3	$21M	Hold	6,995,861	–	–	0.71%	27
2023 Q2	$26.2M	Buy	6,995,861 +811,000	+13%	+$3.04M	0.64%	22
2023 Q1	$20.7M	Hold	6,184,861	–	–	0.67%	27
2022 Q4	$29.7M	Hold	6,184,861	–	–	0.91%	21
2022 Q3	$35.2M	Sell	6,184,861 -155,778	-2%	-$1.19M	1.04%	22
2022 Q2	$45M	Hold	6,340,639	–	–	1.55%	20
2022 Q1	$45.8M	Buy	6,340,639 +964,505	+18%	+$6.55M	1.43%	20
2021 Q4	$48.1M	Buy	+5,376,134	New	+$83.8M	1.53%	20

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's AVIR Position: Q1 2025 in Review

EcoR1 Capital sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 3,341,653 shares — an estimated $11.2M sold.

EcoR1 Capital first reported a position in AVIR in Q4 2021 and held it in 13 quarters. The position peaked at $48.1M in Q4 2021. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

EcoR1 Capital reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
EcoR1 Capital sold 3,341,653 Atea Pharmaceuticals shares in Q1 2025, an estimated $11.2M.
EcoR1 Capital first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 13 quarters.
EcoR1 Capital's Atea Pharmaceuticals position peaked at $48.1M in Q4 2021.
103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.